Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-101 in moderate to severe ulcerative colitis
NCT04583358Phase 2Unknown
- Sponsor
- Applied Molecular Transport
- Start
- Aug 2020
- Primary completion
- Nov 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 2 trial of AMT-101 in ulcerative colitis (UC), sponsored by Applied Molecular Transport. Status: unknown.
02
Drugs
AMT-101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04583358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583358.